Associated Papers
Clinical relevance of the somatic mutational landscaping in predicting outcome of bladder cancer patients.
Nedjadi T et al.
Scientific Reports, 2025
Reannotation of cancer mutations based on expressed RNA transcripts reveals functional non-coding mutations in melanoma.
Pepe D et al.
American Journal of Human Genetics, 2025
40359938 (PubMed )
Supplement: mmc6.xlsx › Sheet_1
A transcriptional network of cell cycle dysregulation in noninvasive papillary urothelial carcinoma.
Warrick JI et al.
Scientific Reports, 2022
36192513 (PubMed )
Supplement: 41598_2022_20927_MOESM14_ESM.xlsx › mutations
Detection of Cancer Mutations by Urine Liquid Biopsy as a Potential Tool in the Clinical Management of Bladder Cancer Patients.
Ibrahim NK et al.
Cancers, 2022
35205727 (PubMed )
Supplement: cancers-14-00969-s001.zip › cancers-1533743-Supplementary_Tables.xlsx › Table_S6
Somatic FGFR3 Mutations Distinguish a Subgroup of Muscle-Invasive Bladder Cancers with Response to Neoadjuvant Chemotherapy.
Yang Z et al.
Ebiomedicine, 2018
TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.
Wang K et al.
The Oncologist, 2015
Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer.
Gust KM et al.
Molecular Cancer Therapeutics, 2013
FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer.
Tomlinson DC et al.
The Journal of Pathology, 2007
Spectrum of FGFR3 mutations in multiple intraindividual seborrheic keratoses.
Hafner C et al.
The Journal of Investigative Dermatology, 2007
Early-onset low-grade papillary carcinoma of the bladder associated with Apert syndrome and a germline FGFR2 mutation (Pro253Arg).
Andreou A et al.
American Journal of Medical Genetics. Part A, 2006
Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.
Zieger K et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2005
16278391 (PubMed )
Supplement: 10780432ccr051130-sup-ccr_11-1-05_zieger.pdf
FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.
Jebar AH et al.
Oncogene, 2005
Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens.
Wallerand H et al.
Carcinogenesis, 2005
The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer.
Ouerhani S et al.
Cancer Biomarkers : Section a of Disease Markers, 0
Select a paper to view details